Faeth Therapeutics, Inc. has announced the appointment of Adam Schayowitz as a Class III director, effective immediately. This decision, made on October 23, 2026, expands the Board of Directors from six to seven members. The addition of Schayowitz is significant as it aims to bolster the company’s leadership and strategic direction in the competitive pharmaceutical industry.

Faeth Therapeutics, based in Austin, Texas, specializes in pharmaceutical preparations, focusing on innovative therapies for oncology. The company trades on the Nasdaq under the ticker symbol FTH and is classified under the SIC code 2834. As an emerging growth company, Faeth is actively working to enhance its market presence and product offerings.

The SEC filing reveals that Schayowitz, 46, has a robust background in drug development, having served as Executive Vice President and Head of Research and Development at Zymeworks Inc. since April 2026. His previous roles include Acting Chief Development Officer at Zymeworks and leadership positions at Pfizer Oncology, where he was involved in various cancer treatment developments. His extensive experience is expected to bring valuable insights to Faeth’s Board.

In his new role, Schayowitz will receive a cash retainer and an initial equity award, which includes options to purchase 25,000 shares of the company’s common stock. These options will vest over a period of three years and will fully vest upon a change in control, reflecting the company’s commitment to aligning director compensation with shareholder interests.

There are no disclosed family relationships between Schayowitz and any other executive officers or directors at Faeth. Additionally, he is not involved in any transactions that require disclosure under SEC regulations. Schayowitz will enter into a standard indemnification agreement for executive officers and directors, ensuring protection against potential liabilities.

This strategic appointment is part of Faeth Therapeutics' ongoing efforts to strengthen its leadership and enhance its capabilities in the pharmaceutical sector. As the company continues to navigate the competitive landscape, the expertise brought by Schayowitz is anticipated to play a critical role in shaping its future initiatives.

Looking ahead, Faeth Therapeutics may provide further updates regarding its strategic plans and potential developments in upcoming filings. The filing does not specify what actions will follow this appointment.